Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAINS: Bevacizumab vs corticosteroids for symptomatic cerebral radiation necrosis
2024-512466-34-00Phase 3Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in brain radionecrosis, high-grade glioma (HGG) and brain metastases (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Favourable clinical response at 12 weeks. Planned start Feb 2025; status: authorised.
02
Drugs
bevacizumab
03
Conditions
brain radionecrosishigh-grade glioma (HGG)brain metastases
Beyond the preview
Go deeper on 2024-512466-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512466-34-00.